DEINOVE Logo

DEINOVE

Develops compounds from rare bacteria for cosmetics and new antibiotics.

ALDEI | PA

Overview

Corporate Details

ISIN(s):
FR0010879056 (+1 more)
LEI:
969500BEJSRFER0F2K08
Country:
France
Address:
1682 RUE DE LA VALSIERE, 34790 GRABELS

Description

DEINOVE is a biotechnology company that discovers, develops, and produces high-value compounds derived from rare bacteria and microorganisms, often referred to as 'microbial dark matter'. Leveraging a proprietary technology platform, the company harnesses the metabolic potential of extremophilic bacteria, such as Deinococcus, to create innovative solutions. Its primary applications are focused on developing novel bio-based active ingredients, including carotenoids, for the cosmetics sector, and discovering new antibiotics to address the global challenge of antimicrobial resistance.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-01-24 17:45
Conversion de la procédure de redressement judiciaire en liquidation judiciaire
French 80.4 KB
2023-01-24 17:45
Conversion of the receivership proceedings into judicial liquidation proceedings
English 67.6 KB
2023-01-16 19:09
DEINOVE - Point sur la procédure de redressement judiciaire
French 79.4 KB
2023-01-16 19:09
DEINOVE - Update on the receivership proceedings
English 66.5 KB
2022-12-16 18:10
DEINOVE - Point sur la Procédure de Redressement Judiciaire
French 80.2 KB
2022-12-16 18:10
DEINOVE - Update on the Receivership Proceedings
English 67.5 KB
2022-11-07 17:45
Deinove annonce L’ouverture d’une procédure de redressement judiciaire
French 72.0 KB
2022-11-07 17:45
Deinove Announces the Opening of Receivership Proceedings
English 89.5 KB
2022-10-28 17:51
DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS
English 67.6 KB
2022-10-28 17:51
DEINOVE SOLLICITE UNE PROCÉDURE DE REDRESSEMENT JUDICIAIRE
French 68.6 KB
2022-10-20 17:45
DEINOVE - Adoption of the resolutions at the Shareholders’ Extraordinary Genera…
English 69.8 KB
2022-10-20 17:45
DEINOVE - Adoption de l'ensemble des résolutions de son Assemblée Générale Extr…
French 71.2 KB
2022-10-10 17:45
DEINOVE - Extraordinary General Meeting of October 17, 2022: Appointment of an …
English 86.3 KB
2022-10-10 17:45
DEINOVE- Assemblée générale extraordinaire du 17 octobre 2022 : Désignation d'u…
French 88.2 KB
2022-10-06 19:02
DEINOVE présente ses résultats financiers et l’avancée de ses programmes pour l…
French 239.0 KB

Automate Your Workflow. Get a real-time feed of all DEINOVE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DEINOVE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DEINOVE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genprex, Inc. Logo
Clinical-stage gene therapy company developing therapies for cancer and diabetes.
United States of America
GNPX
Genxone Spolka Akcyjna Logo
A biotechnology company specializing in Next Generation Sequencing and medical diagnostics.
Poland
GX1
GeoVax Labs, Inc. Logo
Clinical-stage biotech developing vaccines and therapies for infectious diseases and cancer.
United States of America
GOVX
GH Research PLC Logo
Develops mebufotenin-based therapies for psychiatric and neurological disorders.
United States of America
GHRS
GI Innovation Inc. Logo
Researches and develops protein-based drugs for immuno-oncology and immunology.
South Korea
358570
Ginkgo Bioworks Holdings, Inc. Logo
Operates a horizontal platform for cell programming and synthetic biology.
United States of America
DNA
GRAIL, Inc. Logo
A healthcare company developing blood tests for multi-cancer early detection.
United States of America
GRAL
GT Biopharma, Inc. Logo
Clinical-stage immuno-oncology company developing therapies with its NK cell engager tech.
United States of America
GTBP
Guard Therapeutics International AB Logo
Clinical-stage biotech developing therapies to prevent acute kidney injury.
Sweden
GUARD
Gubra A/S Logo
Biotech and CRO focused on peptide drugs for metabolic and fibrotic diseases.
Denmark
GUBRA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.